Navigation Links
SCOLR Pharma's Partner to Commence Bioequivalence Study of Ondansetron
Date:2/14/2012

BOTHELL, Wash., Feb. 14, 2012 /PRNewswire/ -- SCOLR Pharma, Inc. (OTCQB: SCLR) announced today that RedHill Biopharma Ltd., a license partner that had previously obtained the exclusive worldwide rights to use SCOLR's patented technology to develop a new version of ondansetron, will conduct a bioequivalence trial in Canada.  Both the US Food and Drug Administration (FDA) and Health Canada have reviewed the protocol for the study and have no objections.

RedHill submitted an Investigational New Drug application (IND) to the FDA and a Clinical Trial Application (CTA) to Health Canada seeking permission to compare the bioequivalence of its product, which it calls RHB-102, to Zofran® (ondansetron), which is manufactured by GlaxoSmithKline.  Zofran® is an anti-emetic drug (i.e. for prevention of nausea and vomiting) that is administered several times per day. RHB-102 is a once-daily controlled release tablet formulation of ondansetron, a serotonin 5-HT3 receptor antagonist.

RedHill Biopharma said publicly, based on advice received from its regulatory consultants, that subject to certain conditions, the study may be considered a pivotal trial (Phase III-equivalent) that may be used by the Company for a marketing application to the FDA.  RedHill Biopharma estimated the development costs of RHB-102, until submission of an application to the FDA, will total $2-3 million. 

Stephen Turner, President and CEO of SCOLR, said: "We believe that the RedHill Biopharma announcement again affirms the potential value of SCOLR's patented technology in developing new pharmaceuticals that improve on existing drugs.  We look forward to a successful outcome on this study and a promising ongoing relationship with RedHill."

About SCOLR Pharma:

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT® platforms to deve
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. SCOLR Pharma, Inc. Announces Initial Shipments of its Nutritional Products
2. SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results
3. SCOLR Pharma, Inc. First Quarter 2011 Financial Results
4. SCOLR Pharma, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference
5. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
6. SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application
7. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
8. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
9. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
10. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
11. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... VALLEY, Calif. , May 4, 2015 ... biologic for psoriasis, today announced that preclinical and mechanism ... session at the Society of Investigative Dermatology (SID) Annual ... Atlanta, in Atlanta, Georgia . ... is advancing the development of RON2315, a novel, low ...
(Date:5/4/2015)...   HeartWare International, Inc . (NASDAQ: HTWR ), ... that are revolutionizing the treatment of advanced heart failure, today ... scheduled to present at the Bank of America Merrill Lynch ... on Thursday, May 14, 2015, at 10:00 a.m. PT ... Company,s presentation at the conference will be available via a ...
(Date:5/4/2015)... , May 4, 2015 Unchained Labs, a ... to this year,s PEGS conference and launches the UNit ... for biologics. PEGS: The Essential Protein Engineering Summit takes ... 2015. The UNit lets drug discovery researchers ... tool out there. Its 7 applications, 144 sample a ...
Breaking Medicine Technology:Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Unchained Labs Lets the UNit Loose 2
... Ambrx Inc. today announced that Ho Cho, Ph.D., ... from the company,s antibody drug conjugate (ADC) programs at ... obtained from recent xenograft studies comparing Ambrx ADCs with ... technology has been clinically validated as safe and efficacious ...
... 22, 2011 Naurex Inc., a clinical-stage ... psychiatry and neurology, today announced that it has initiated ... GLYX-13.  GLYX-13, a Glycine-site Functional Partial Agonist (GFPA) selective ... developed as a therapy for patients who are not ...
Cached Medicine Technology:Ambrx to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences 2Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 2Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression 3
(Date:5/4/2015)... Now in its seventh year, the IPC ... made outstanding contributions to the company, to their facilities ... and post-acute care settings. The five award categories are: ... Year, Advanced Practice Clinician of the Year, Newcomer Provider ... Recipients are selected by IPC’s senior management team. , ...
(Date:5/4/2015)... 04, 2015 EyeCRO LLC and NeuMedics ... facilitate development of NM108, a first-in-class small molecule to ... blindness, including Diabetic Retinopathy. The collaboration grants NeuMedics ... EyeCRO, which can deliver drugs to the front and ... , Under the terms of the agreement, EyeCRO will ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Ticket Down is ... the Colonial Life Arena in Columbia, South Carolina. ... continuation of his “Out There” tour which originally kicked off ... tour is North America and the legendary performer recently announced ... the Wells Fargo Arena on June 21st, in Charlottesville, VA ...
(Date:5/4/2015)... UT (PRWEB) May 04, 2015 Pricing ... (up to $3,000) of one patient receiving care at ... Utah. The procedure must be performed by July 15th, ... to pay in full up front and forego the filing ... becomes more economically burdensome every year, and it devastates more ...
(Date:5/4/2015)... Atlanta, GA (PRWEB) May 04, 2015 ... in Atlanta, Georgia proudly offers the latest non-surgical double-chin ... the only facial plastic surgeon in Atlanta to offer ... Kybella drug to be injected specifically under the chin, ... ‘double-chin’ appearance. , Before Kybella, patients who sought immediate ...
Breaking Medicine News(10 mins):Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 2Health News:Pricing Healthcare to Pay a Patient's Bill for a Procedure at Utah Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2
... American Heart Association's online heart disease education program were ... reported at the American Heart Association's 8th Scientific ... Cardiovascular Disease and Stroke. ,Those who used ... program developed with Thomson Healthcare also were more ...
... have intensified monitoring of over 800 poultry farms in the ... farms there, an official said Saturday. ... farms May 22 and in two other farms the next ... reported, quoting Livestock Commissioner R.H Usmani. ,Several thousand ...
... persons attitude that determines how much exercise is too much ... Clinic. ,The researchers say that people who ... benefits it provides have the right reason in mind, but ... spite of injuries may be at a risk of developing ...
... the Blue Moon will be possible after midnight of June 1. ... full Moons occur within a calendar month, that the second full ... you live London, you will officially have to wait until June ... to astronomers and cosmologists, May 31 will brings us the second ...
... Pitt is enjoying parental bliss to the fullest. ... Pitt poured his heart out about the delight and joys of ... They're mind-blowing. Get ready to change no end of dirty diapers. ... ever happened to me,' the Mirror quoted Pitt, as saying. ...
... have discovered mutations in the DNA of four genes ... cancer in women . ,The discovery would ... higher-than-average risk of breast cancer so that they could ... the age when routine breast screening now begins. ...
Cached Medicine News:Health News:Online Education Program Better Source of Information for Patients 2Health News:Online Education Program Better Source of Information for Patients 3Health News:Attitude Determines How Much Exercise is too Much 2Health News:Blue Moon at Midnight from June 1 2Health News:UK Scientists Identify Gene Mutations That Trigger Breast Cancer 2Health News:UK Scientists Identify Gene Mutations That Trigger Breast Cancer 3
... Chart Manager information can be input ... are not limited to drop-down lists ... each person to document individually. Patient ... valuable data and communication. All this ...
AllMeds was the first specialty-specific Electronic Medical Record for Orthopaedics. Instead of trying to force a general-purpose EMR into your practice, AllMeds starts with clinical content from Ort...
... software It runs over hospital ... PAS systems and some items ... collects data at initial consultation, ... checks, operation, post-op checks, telephone ...
... such as prescription writing, referral letters, chart ... will be ,able to add more appointments ... staff., Based on the exam documentation created ... recommend the appropriate E&M ,code for the ...
Medicine Products: